VYNE Therapeutics Inc (VYNE)
NASDAQ
News
Market Data
Register for real-time alerts, custom portfolio, and market movers
The current VYNE market cap is 29.35M. The company's latest EPS is USD -1.9290 and P/E is -1.03.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 135k | 114k | 76k | 98k | 198k |
| Operating Income | -10.32M | -6.23M | -6.83M | -7.38M | -10.4M |
| Net Income | -10.06M | -6.58M | -6.19M | -6.25M | -9.41M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 20.99M | 14.76M | 477k | 424k |
| Operating Income | -76.24M | -198.2M | -68.03M | -34.3M | -29.26M |
| Net Income | -73.7M | -255.83M | -73.33M | -23.21M | -28.45M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 24.96M | 19.27M | 97.69M | 91.68M | 86.65M |
| Total Liabilities | 7.69M | 7.76M | 8.95M | 8.31M | 11.78M |
| Total Equity | 17.27M | 11.51M | 88.74M | 83.37M | 74.87M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 79.17M | 93.74M | 67.05M | 40.76M | 97.69M |
| Total Liabilities | 10.66M | 56.25M | 18.41M | 9.35M | 8.95M |
| Total Equity | 68.51M | 37.49M | 48.64M | 31.2M | 88.74M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -15.05M | -20.2M | -25.34M | -7.98M | -16.46M |
| Investing | 5M | 5M | -57.35M | -3.57M | 15.45M |
| Financing | -222k | -269k | 82.39M | -4k | -7k |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -65.1M | -137.08M | -56.37M | -29.2M | -25.34M |
| Investing | 41.37M | 89.11M | 1.03M | 15.67M | -57.35M |
| Financing | 4.99M | 61.81M | 39.78M | 1.65M | 82.39M |
| Market Cap | 29.35M |
| Price to Earnings Ratio | -1.03 |
| Price to Sales Ratio | 69.34 |
| Price to Cash Ratio | 0.96 |
| Price to Book Ratio | 0.33 |
| Dividend Yield | - |
| Shares Outstanding | 14.75M |
| Average Volume (1 week) | 41.06k |
| Average Volume (1 Month) | 35.24k |
| 52 Week Change | -41.47% |
| 52 Week High | 4.4808 |
| 52 Week Low | 1.57 |
| Spread (Intraday) | 0.41 (20.5%) |
| Company Name | VYNE Therapeutics Inc |
| Address |
1521 concord pike suite 201 wilmington, delaware 19810 |
| Website | https://vynetherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
